Lent score and informed management decisions in malignant pleural effusions (MPE). When is little too much?

G. Hardavella (Athens, Greece), M. Xigki (Athens, Greece), I. Karampinis (Athens, Greece), A. Tzonou (Athens, Greece), I. Kainis (Athens, Greece)

Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Session: Symptoms, risks, complications and palliative care in thoracic oncology
Session type: Thematic Poster
Number: 4656
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Hardavella (Athens, Greece), M. Xigki (Athens, Greece), I. Karampinis (Athens, Greece), A. Tzonou (Athens, Greece), I. Kainis (Athens, Greece). Lent score and informed management decisions in malignant pleural effusions (MPE). When is little too much?. 4656

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
ERS/EACTS statement on the management of malignant pleural effusions
Source: Eur Respir J, 52 (1) 1800349; 10.1183/13993003.00349-2018
Year: 2018



ERS/EACTS statement on the management of malignant pleural effusions
Source: Guideline 2018
Year: 2018

Are patients with malignant pleural effusions being referred appropriately for surgical intervention?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Understanding how variation in clinical practice affects length of stay for patients with malignant pleural effusion.
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019

A randomised controlled study comparing the outcomes of pleural nurse practitioner (NP) versus doctors trained to perform pleural procedures for management of pleural effusions
Source: Annual Congress 2013 –Interventional pulmonology and pleural diseases
Year: 2013


Optimal management of symptomatic malignant pleural effusions: individualised care
Source: Virtual Congress 2021 – Hot news from the pleura
Year: 2021


Time to diagnosis and time to therapy in patients with malignant pleural mesothelioma (MPM) compared to patients with lung cancer in Denmark 2007 to 2011. A quality assurance analysis
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012


Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion
Source: Eur Respir J 2006; 28: 409-422
Year: 2006


A Dutch web-survey on management of malignant pleural effusions
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011


How often is a single therapeutic aspiration sufficient to manage a malignant pleural effusion and does oncological treatment have an impact on this?
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019

Difficult pleural effusion management (e.g., chylothorax, trapped lung and rheumatoid effusions)
Source: International Congress 2017 – PG5 Pleural disease management
Year: 2017


Is pleural VEGF a useful parameter?
Source: Annual Congress 2007 - Pleural malignancy
Year: 2007


Immunotherapy for malignant pleural mesothelioma: ready for clinical practice?
Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?
Year: 2016


Optimal diagnosis and treatment of malignant pleural disease: challenging the guidelines
Source: Eur Respir Monogr 2020; 87: 138-154
Year: 2020


Heterogeneous delivery of definitive interventions in malignant pleural effusions – results from a Danish survey.
Source: International Congress 2019 – Pleural disease: applying the evidence
Year: 2019


Diagnosis of malignant pleural mesothelioma: the clinician and pathologist points of view
Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines
Year: 2009


Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion?
Source: International Congress 2017 – Pleural and mediastinal malignancies
Year: 2017


ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Source: Eur Respir J, 55 (6) 1900953; 10.1183/13993003.00953-2019
Year: 2020



Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005


Medical thoracoscopy at patients with pleural effusion: Diagnostics and treatment, what‘s more?
Source: Annual Congress 2010 - Video-assisted thorascopic surgery, novel technical devices and tracheal problems
Year: 2010